Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome

Summary

The aim of study is to assess the angioprotective effects of antihypertensive combination therapy with perindopril 10 mg and moxonidine 0.4-0.6 mg in patients with arterial hypertension, metabolic syndrome, and obesity, who had Pulse Wave Velocity (PWV) \> 10 m/s on the previously administered two-component combination antihypertensive therapy. Open-label non-comparative prospective study for 24 week for each patient.

Timeline

Start

2019-03-11

Primary completion

2020-06-30

Completion

2020-12-30

Drugs

Indications